Navigation Links
Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 46th American Society of Clinical Oncology Annual Meeting

EMERYVILLE, Calif., May 20 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8, 2010 in Chicago, IL.  Presentations will highlight data from the carfilzomib development program in patients with relapsed/refractory multiple myeloma and solid tumors.  Each presentation will include updated data at the annual meeting that will not be available in the online abstracts at

"We are further encouraged by the growing body of evidence that supports carfilzomib's potential as a new treatment option for patients with multiple myeloma," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development at Onyx.  "We look forward to sharing final data from our Phase 2b 003-A1 pivotal trial that we anticipate will form the basis of an initial New Drug Application (NDA) filing for carfilzomib by year end."

Carfilzomib data presentations:

Multiple Myeloma

Results of an Ongoing Open-Label, Phase 2 Study of Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (MM)

  • Dr. Ravi Vij, Washington University School of Medicine
  • Saturday, June 5, 2010, 4:30 - 6:00 p.m., E354a
  • Clinical Science Symposium: Lymphoma and Plasma Cell Disorders
  • Abstract #8000

Dose Escalation Study of Carfilzomib Plus Lenalidomide and Low Dose Dexamethasone (CRd) in Relapsed and Refractory Multiple Myeloma (MM)

  • Dr. William Besinger, University of Washington School of Medicine
  • Friday, June 4, 2010, 8:00 a.m. - 12:00 p.m., S Hall A2
  • Poster session: Lymphoma and Plasma Cell Disorders
  • Abstract #8029, poster board 8

Phase 2 Study of Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma and Renal Insufficiency (MM)

  • Dr. Ashraf Badros, University of Maryland School of Medicine
  • Saturday, June 5, 2010, 9:00 a.m. - 12:00 p.m., S Hall A2
  • Poster session: Lymphoma and Plasma Cell Disorders
  • Abstract #8128, poster board 36F

Neurotoxic and Peripheral Neuropathic Effects in Preclinical and Clinical Studies of Carfilzomib, a Novel Proteasome Inhibitor (PI)

  • Dr. Jeffrey Wolf, University of California San Francisco Comprehensive Cancer Center
  • Saturday, June 5, 2010, 8:00 - 12:00 p.m., S Hall A2
  • Poster session: Lymphoma and Plasma Cell Disorders
  • Abstract #8135, poster board 37E

Solid Tumors & Multiple Myeloma

Updated Results of a Phase 1b/2 Study of Carfilzomib in Patients with Relapsed Malignancies

  • Dr. Peter Lee, Tower Cancer Research Foundation
  • Saturday, June 5, 2010, 8:00 a.m. - 12:00 p.m., S Hall A2
  • Poster session: Lymphoma and Plasma Cell Disorders
  • Abstract #8147, poster board 39A

About the Carfilzomib Development Program

Carfilzomib is a selective, next generation proteasome inhibitor that has shown encouraging results in a broad clinical trial program in multiple myeloma.

In addition, the company intends to initiate a large, randomized international Phase 3 clinical trial, known as the 009 trial, this year to study the combination of lenalidomide and low dose dexamethasone with or without carfilzomib in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMEA) on the design and planned analysis of the 009 trial. A second Phase 3 clinical trial, the 011 trial, of carfilzomib in relapsed and refractory myeloma is planned in Europe. Carfilzomib is also being evaluated in advanced solid tumors.

About Multiple Myeloma

Multiple myeloma (MM) is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow. In the United States, more than 50,000 people are living with MM and approximately 20,000 new cases are diagnosed annually.(i) Worldwide, more than 180,000 people are living with MM and approximately 86,000 new cases are diagnosed annually.(ii)

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801 is a targeted alpha-folate inhibitor currently in Phase 1 testing. For more information about Onyx, visit the company's website at

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.

Forward Looking Statements

This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws.  These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, safety, regulatory processes, commercialization efforts or commercial potential of carfilzomib.  These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the development and commercialization of pharmaceutical products.  Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements.  Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2009, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors.  Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release.  Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.  

(i)National Cancer Institute, Surveillance Epidemiology and End Results, 2007 Facts and Figures

(ii)International Agency for Research on Cancer, GLOBOCAN 2002 database

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
(Date:11/30/2015)... 2015 North America was ... grow at a CAGR of 7.6% from 2015 to 2020. ... 135.6 million in 2014, and is expected to grow at a ... to the new Market Research Report "North America Cardiac Output Monitoring ... (Hospitals, ambulatory care, others) - Analysis And Forecast To 2020", the ...
(Date:11/30/2015)... --> --> ... by Product (Soft Tissue, All Tissue, Dental Welding Lasers), Application ... Geography - Global Forecast to 2020", published by MarketsandMarkets, is ... CAGR of 5.2% during the forecast period from 2015 to ... 62 Figures spread through 167 P ages and in-depth ...
(Date:11/30/2015)... MOUNTLAKE TERRACE, Wash. and ST. ... Cross and Express Scripts (NASDAQ: ESRX ) today ... benefit agreement. The partnership, which began in 1999, will ... --> --> After evaluating pharmacy ... process, Premera concluded that Express Scripts continues to offer ...
Breaking Medicine Technology:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... Foundation (Meso Foundation) released information for caregivers and held two webinars on topics ... available on demand free of charge at . , With a ...
(Date:11/30/2015)... ... November 30, 2015 , ... Thermi™, a world ... announce that its ThermiRFR temperature controlled radiofrequency platform has received CE marking and ... platform which uses temperature as a clinical endpoint. The technology has been ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... vehicle experience this summer, ushering in a new era of publicly accessible automated ... electric shuttle, will continue to offer guests an up-close look at the shuttle ...
(Date:11/30/2015)... ... November 30, 2015 , ... On Saturday, October 24th, 2015, at the Mill ... fundraising event, a 5K walk known as “Making Strides Against Breast Cancer”. Patients and ... is also located in Battle Creek, joined in for this campaign that sought to ...
(Date:11/30/2015)... ... November 30, 2015 , ... During the week of ... raise funds for its research, education, support, and advocacy efforts. The campaign is ... , The Mesothelioma Applied Research Foundation, which also goes by Meso Foundation, holds ...
Breaking Medicine News(10 mins):